 Shares of Biogen Inc NASDAQ: BIIB have gained nearly 45 since late September but CEO Christopher Viehbacher says theres still a lot thats underestimated at Biogen. Highlights from CEOs interview with CNBC Viehbacher is convinced that the likes of Lecanemab and Zuranolone will contribute significantly to future growth. 